Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

Moderna (MRNA) Stock Surges 169% Despite Wall Street Skepticism

📈 Moderna stock hit a 52-week high of $81.42 on July 6, representing a 169% total return over the past year.

🏥 The FDA advisory panel unanimously endorsed Moderna's experimental seasonal flu vaccine (mRNA-1010) for individuals aged 50 and older.

🧬 mRNA-6007, an in vivo CAR-T therapy for autoimmune diseases like systemic lupus erythematosus, advanced into preliminary development.

💰 Q1 revenue jumped 260% year-over-year to $389 million, significantly exceeding the analyst estimate of $236.37 million.

📉 Analyst consensus remains 'Reduce' with a mean price target of $37.13, less than half of the current trading price.

🏦 Goldman Sachs raised its price target to $49 while maintaining a neutral rating on the stock.

📉 Corporate insiders sold 125,088 shares totaling over $6.1 million during the previous 90-day period.

🏛️ Board member Noubar Afeyan reduced his position by 70.24% by selling 9,263 shares on May 21.

📊 Institutional ownership stands at 75.33%, with Louisiana State Employees Retirement System establishing a new position of 17,700 shares.

📉 Moderna reported Q1 earnings per share of -$3.40, missing the consensus forecast of -$3.02.

Bullish Signals
  • Moderna stock reached a fresh 52-week peak of $81.42, delivering a remarkable 169% annual increase and a 124% climb over six months.
  • Q1 revenue surged 260.2% year-over-year to $389 million, significantly beating the analyst estimate of $236.37 million.
  • The FDA advisory panel delivered a unanimous endorsement for Moderna's experimental seasonal influenza vaccine (mRNA-1010) for the 50-and-over demographic.
  • Moderna disclosed that its mRNA-6007 in vivo CAR-T initiative is advancing into preliminary development targeting autoimmune conditions like systemic lupus erythematosus.
  • Institutional investors are accumulating shares, with Louisiana State Employees Retirement System establishing a fresh position of 17,700 shares valued at approximately $899,000.
Risk Factors
  • Wall Street analysts hold an average 'Reduce' stance with a consensus price objective of $37.13, representing less than 50% of current trading levels.
  • Corporate insiders have offloaded 125,088 shares totaling more than $6.1 million over the previous 90 days, indicating potential lack of confidence at current valuations.
  • Q1 earnings per share registered at -$3.40, falling short of the consensus forecast of -$3.02 despite strong revenue growth.
  • InvestingPro analytics position the equity among the platform's most overextended securities when measured against its Fair Value assessment.
Full Analysis
Moderna (MRNA) shares surged to a 52-week peak of $81.42 on July 6, marking a 169% annual gain and pushing the market cap to approximately $32.2 billion. This rally was driven by renewed enthusiasm for mRNA technology, including FDA advisory panel endorsement for its seasonal influenza vaccine (mRNA-1010) for adults over 50, and progress on its in vivo CAR-T initiative targeting autoimmune conditions. Despite the stock price momentum, Wall Street analysts maintain a cautious stance with an average 'Reduce' rating and a consensus price target of $37.13, significantly below current trading levels. Goldman Sachs raised its projection to $49 while maintaining a neutral stance, whereas Bank of America and Barclays adjusted targets upward but kept underperform or equal weight ratings respectively. Financial performance in Q1 showed mixed results with revenue surging 260% year-over-year to $389 million, beating estimates, though EPS missed at -$3.40 versus a forecast of -$3.02. While institutional investors like Louisiana State Employees Retirement System expanded holdings, corporate insiders collectively sold over 125,000 shares worth more than $6.1 million in the last 90 days.